Withings Body Scan 2 Debuts at CES 2026 with $599.95 Price Tag
Withings announced the $599.95 Body Scan 2 at CES 2026. This advanced smart scale uses 12 electrodes and a retractable handle for precise cardiovascular and metabolic tracking.
Is a scale ever worth $599.95? Withings thinks so. At CES 2026, the health tech pioneer unveiled the Body Scan 2, a high-end smart scale designed to be a comprehensive health station rather than just a weight measurement tool.
Advanced Sensors in Withings Body Scan 2
According to reports from The Verge, the Body Scan 2 features a sophisticated array of 12 electrodes in total. While most smart scales rely solely on foot electrodes, this model includes a retractable handle with four additional electrodes. This configuration allows the device to capture upper-body data, providing a far more accurate picture of total body composition and metabolic health.
Release Timeline and FDA Status
The device is slated for a Q2 2026 release, pending FDA clearance for its specific medical metrics. Its primary focus has shifted toward cardiovascular health and metabolic monitoring, positioning it as a proactive tool for users tracking chronic conditions or longevity goals.
Authors
Related Articles
From period trackers to newborn blood samples, the data our bodies generate is being harvested, sold, and subpoenaed. A deep look at who benefits—and who pays the price.
Since FDA approval in 2022, the hearing aid market has transformed dramatically. Low-cost alternatives are disrupting traditional medical devices, sparking an accessibility revolution.
Fitbit founders James Park and Eric Friedman launch Luffu, an AI-powered family health platform that shifts focus from individual tracking to coordinated family caregiving.
BioticsAI has secured FDA clearance for its AI-powered fetal abnormality detection software. The 2023 TechCrunch Disrupt winner aims to combat U.S. maternal health disparities through automation.
From period trackers to newborn blood samples, the data our bodies generate is being harvested, sold, and subpoenaed. A deep look at who benefits—and who pays the price.
Since FDA approval in 2022, the hearing aid market has transformed dramatically. Low-cost alternatives are disrupting traditional medical devices, sparking an accessibility revolution.
Fitbit founders James Park and Eric Friedman launch Luffu, an AI-powered family health platform that shifts focus from individual tracking to coordinated family caregiving.
BioticsAI has secured FDA clearance for its AI-powered fetal abnormality detection software. The 2023 TechCrunch Disrupt winner aims to combat U.S. maternal health disparities through automation.
Thoughts
Share your thoughts on this article
Sign in to join the conversation